“A CO-RELATION OF FIRST TRIMESTER LEVELS OF PAPP-A (PREGNANCY ASSOCIATED PLASMA PROTEIN A) AND PIGF (PLACENTA INDUCED GROWTH FACTOR) WITH CO RELATION OF PREECLAMPSIA AND FETOMATERNAL OUTCOME.”

Abstract

Introduction: Preeclampsia is one of the major cause of maternal and fetal mortality. Pathogenesis of development of preeclampsia is still not clear but one of the cause is considered to be abnormal placentation. Various markers haven been found to be involved in process of placentation among which PAPP-A and PIGF have been found to be actively involved. PAPP-A and PIGF levels have not been studied in the Indian population in terms of preeclampsia prediction at 10-14 weeks of gestation, and we intend to study their levels for early preeclampsia prediction. Methodology: This observational study was carried out in obstetrics and gynecology OPD , Sir T Hospital , Bhavnagar from June-2021 to August 2022. Total of 100 antenatal patients attending OPD who were in rst trimester taken after considering inclusion and exclusion criteria. Investigations for PAPP-A and PIGF were taken and patient followed up for development of preeclampsia till delivery. Incidence of preeclampsia was found to be 22%. Majority of patients Results: were found in age group of 26-30 years. More number of patients were multigravida who developed preeclampsia. PAPP-A during rst trimester were found as 1.06 ± 0.20 MoM in overall patients, while PIGF found as 0.97 ± 0.18 MoM. Moreover, mean PAPP-A and PIGF of control and case group were found as (1.11 ± 0.22 MoM vs 0.91 ± 0.21 MoM; p<0.0001) and (0.99 ± 0.17 MoM vs 0.88 ± 0.20 MoM; p<0.0001) respectively. 90% of babies delivered full term. In women with preeclampsia 10% patients had preterm delivery. 50% babies were low birth weight in women who developed preeclampsia. Keepi Conclusion: ng the complications associated with preeclampsia, measurement of PAPP-A and PIGF levels in rst trimester can be used as marker for prediction of preeclampsia in later months of pregnancy. Levels if found lower can help in taking regular follow up of patients and early diagnosis and management can be done. This can help us prevent maternal as well as fetal morbidity and mortality.